Shanghai Henlius (2696) Announces Approval for H Share Full Circulation

Bulletin Express01-19 22:41

Shanghai Henlius Biotech, Inc. (Stock code: 2696) has received listing approval from The Stock Exchange of Hong Kong Limited on 19 January 2026 for the full circulation of 182,645,856 unlisted shares. These converted shares account for approximately 33.61% of the company’s total issued shares and involve 17 participating shareholders.

Upon completion, the largest participating shareholder, Shanghai Fosun New Medicine Research Company Limited, will hold 120,000,000 converted H shares, representing about 22.08% of the company’s total outstanding shares. Overall, the shareholding structure will shift from 69.93% unlisted shares and 30.07% H shares to 36.32% unlisted shares and 63.68% H shares, with the total number of issued shares remaining at 543,494,853.

The company will carry out the necessary conversion and trading procedures for the newly converted H shares and will continue to publish relevant updates. Shareholders and potential investors are advised to exercise caution when dealing in its securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147813290?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-19 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147813290","market":"us","top_or_hot":-1,"title":"Shanghai Henlius (2696) Announces Approval for H Share Full Circulation","media":"Bulletin Express","content":"<p>Shanghai Henlius Biotech, Inc. (Stock code: 2696) has received listing approval from The Stock Exchange of Hong Kong Limited on 19 January 2026 for the full circulation of 182,645,856 unlisted shares. These converted shares account for approximately 33.61% of the company’s total issued shares and involve 17 participating shareholders.</p>\n<p>Upon completion, the largest participating shareholder, Shanghai Fosun New Medicine Research Company Limited, will hold 120,000,000 converted H shares, representing about 22.08% of the company’s total outstanding shares. Overall, the shareholding structure will shift from 69.93% unlisted shares and 30.07% H shares to 36.32% unlisted shares and 63.68% H shares, with the total number of issued shares remaining at 543,494,853.</p>\n<p>The company will carry out the necessary conversion and trading procedures for the newly converted H shares and will continue to publish relevant updates. Shareholders and potential investors are advised to exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Henlius (2696) Announces Approval for H Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Henlius (2696) Announces Approval for H Share Full Circulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-01-19 22:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Henlius Biotech, Inc. (Stock code: 2696) has received listing approval from The Stock Exchange of Hong Kong Limited on 19 January 2026 for the full circulation of 182,645,856 unlisted shares. These converted shares account for approximately 33.61% of the company’s total issued shares and involve 17 participating shareholders.</p>\n<p>Upon completion, the largest participating shareholder, Shanghai Fosun New Medicine Research Company Limited, will hold 120,000,000 converted H shares, representing about 22.08% of the company’s total outstanding shares. Overall, the shareholding structure will shift from 69.93% unlisted shares and 30.07% H shares to 36.32% unlisted shares and 63.68% H shares, with the total number of issued shares remaining at 543,494,853.</p>\n<p>The company will carry out the necessary conversion and trading procedures for the newly converted H shares and will continue to publish relevant updates. Shareholders and potential investors are advised to exercise caution when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"","article_id":"1147813290","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147813290","pubTimestamp":1768833679,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Henlius Biotech, Inc. (Stock code: 2696) has received listing approval from The Stock Exchange of Hong Kong Limited on 19 January 2026 for the full circulation of 182,645,856 unlisted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖"},"translate_title":"复宏汉霖(2696)公布H股全流通获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shanghai Henlius Biotech, Inc. (Stock code: 2696) has received listing approval from The Stock Exchange of Hong Kong Limited on 19 January 2026 for the full circulation of 182,645,856 unlisted shares. These converted shares account for approximately 33.61% of the company’s total issued shares and involve 17 participating shareholders.\nUpon completion, the largest participating shareholder, Shanghai Fosun New Medicine Research Company Limited, will hold 120,000,000 converted H shares, representing about 22.08% of the company’s total outstanding shares. Overall, the shareholding structure will shift from 69.93% unlisted shares and 30.07% H shares to 36.32% unlisted shares and 63.68% H shares, with the total number of issued shares remaining at 543,494,853.\nThe company will carry out the necessary conversion and trading procedures for the newly converted H shares and will continue to publish relevant updates. Shareholders and potential investors are advised to exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147813290","isCrawlerRequest":true}